Core Insights - Auna S.A. and Tenet Healthcare are prominent players in the ambulatory care sector, with Auna focusing on Latin America and Tenet on the U.S. market [1][15] Auna S.A. Overview - Auna operates a differentiated healthcare model in Spanish-speaking Latin America, addressing the fragmented private healthcare market [3] - In Peru, Auna's performance is bolstered by a strong pricing mix and a record low medical loss ratio, alongside a public-private partnership to expand its market [3][4] - The company is experiencing revenue recovery in Mexico, with a focus on expanding its reach to privately insured families and enhancing physician group alignment [4] - Auna is enhancing its oncology capabilities and implementing risk-sharing models in Colombia, which are yielding positive cash flow results [5] - Auna completed a $825 million debt refinancing, improving its capital structure and increasing cash position by 42% [6][7] Tenet Healthcare Overview - Tenet reported net operating revenues of $21.3 billion in 2025, a 14% increase from the previous year, with an adjusted EBITDA margin improvement of 200 basis points to 21.4% [8][12] - The company added 35 facilities to its portfolio in 2025, with a strong pipeline for M&A activity in 2026 [9] - Tenet's Hospital segment saw a 16% adjusted EBITDA growth, with new facility openings supporting capacity expansion [10] - The expiration of enhanced exchange tax credits is expected to impact Tenet's 2026 adjusted EBITDA, leading to lower volume growth [11] - Tenet held $2.88 billion in cash as of December 31, with a free cash flow of $2.53 billion and a leverage ratio of 2.25X EBITDA [12] Market Trends - The global ambulatory healthcare service market is projected to grow at a CAGR of 5.7% from 2026 to 2033, driven by increased demand for outpatient care and advancements in medical technology [2] - Auna's shares have increased by 7.4% year-to-date, while Tenet's shares have decreased by 5.4% [13] - Auna trades at a forward price/sales ratio of 0.31X, lower than its median, while Tenet trades at 0.75X, higher than its median [14] Conclusion - Both Auna S.A. and Tenet Healthcare are well-positioned to capitalize on industry trends, with Auna's strong performance in Peru and recovery in Mexico, and Tenet's steady performance across its segments [15][16] - Auna is currently viewed as the more compelling investment option based on valuation and performance metrics [16]

分组1 - Tenet Healthcare (THC) closed at $188.00, reflecting a -2.01% change from the previous day, underperforming the S&P 500's loss of 0.4% [1] - Over the past month, shares of Tenet Healthcare have decreased by 19.86%, compared to a 10.07% loss in the Medical sector and a 7.34% loss in the S&P 500 [1] 分组2 - Tenet Healthcare is expected to report an EPS of $4.19, indicating a 3.9% decline from the same quarter last year, while revenue is forecasted at $5.39 billion, a 3.15% increase year-over-year [2] - For the annual period, earnings are anticipated to be $17.3 per share and revenue at $21.99 billion, reflecting increases of +3.1% and +3.21% respectively from the previous year [3] 分组3 - The Zacks Rank system, which evaluates estimate changes, currently ranks Tenet Healthcare at 3 (Hold), with a recent 2.37% increase in the consensus EPS estimate over the last 30 days [5] - Tenet Healthcare has a Forward P/E ratio of 11.09, which is in line with the industry average [6] 分组4 - The company has a PEG ratio of 0.93, matching the average for the Medical - Hospital industry, which is currently ranked 52 in the Zacks Industry Rank, placing it in the top 22% of over 250 industries [7][8]

Core Viewpoint - The presentation at the Barclays Global Healthcare Conference features Tenet Healthcare, highlighting its leadership and focus on managed care and facilities [1] Group 1: Company Overview - Tenet Healthcare is represented by its CEO Saum Sutaria, CFO Sun Park, and Vice President of Investor Relations Will McDowell [1] Group 2: Conference Context - The Barclays Global Healthcare Conference serves as a platform for discussing key developments in the healthcare sector, with a focus on investment opportunities [1]

Tenet Healthcare (NYSE:THC) FY Conference Summary Company Overview - **Company**: Tenet Healthcare - **Event**: Barclays Global Healthcare Conference - **Date**: March 10, 2026 Key Points Industry and Market Context - **Demand Environment**: The healthcare demand environment remains strong, particularly in high acuity care sectors, both in ambulatory and acute care settings [3][4] - **Cost Structure Review**: 2026 is seen as a pivotal year for reviewing the organization's cost structure and implementing cost reduction initiatives [4] Financial Performance and Guidance - **EBITDA Growth**: Tenet has achieved mid-teens EBITDA growth over the past two years, with a guidance of 10% core growth for 2026 [3] - **Capital Investments**: Increased capital spending in retained markets is expected to yield returns, supported by a strong market position [4] - **ACA Exchange Headwind**: A projected $250 million headwind from ACA exchange enrollment reduction is included in the 2026 guidance, with an anticipated 20% overall reduction in enrollment [9][10] Operational Insights - **Same-Store Admissions**: A decline in same-store admissions was noted for the first time in three years, with a projected 1%-2% volume growth for 2026 [14][15] - **Commercial Rates**: Commercial rates are tracking in the 3%-5% range, with strong visibility through 2027, attributed to the value Tenet provides to payers [17][19] Technology and Efficiency - **AI Integration**: The use of AI is expected to enhance operational efficiency, automate tasks, and improve asset utilization, particularly in the ambulatory surgery business [6][7][8] - **Revenue Cycle Management**: Conifer's platform is driving significant benefits through workflow automation, coding accuracy, and a globalized workforce, with expectations for further improvements through AI [27][28][29] Strategic Focus Areas - **USPI Growth**: Continued focus on higher acuity, lower volume procedures is expected to drive revenue per case growth in USPI [21][22] - **Inpatient-Only List**: The policy shift is influencing physician recruitment and capital allocation strategies, particularly in urology and spine programs [23][24] - **Site-Neutral Payments**: Ongoing discussions around site-neutral payments are not expected to significantly impact surgical care reimbursement, as Tenet's ASC platform is already aligned with freestanding rates [25][26] Capital Deployment Strategy - **Free Cash Flow**: Tenet anticipates approximately $3 billion in free cash flow for 2026, with plans to balance capital deployment between USPI growth, hospital service line investments, share repurchases, and debt retirement [32] - **Investment Focus**: Investments will prioritize high acuity service lines such as trauma, cardiovascular, and neurosurgery [34] Conclusion - Tenet Healthcare is positioned for continued growth in a strong demand environment, with strategic investments in high acuity care, technology integration, and effective capital deployment strategies to enhance operational efficiency and financial performance [3][4][32]

Core Viewpoint - Tenet Healthcare Corporation (NYSE:THC) is viewed as a strong buy in the healthcare sector, with multiple analysts raising their price targets following the release of its fiscal Q4 financial results and 2026 guidance [1][2]. Financial Performance - Tenet Healthcare reported a net income of $371 million for fiscal Q4, translating to $4.22 per diluted share. The adjusted diluted earnings per share for the quarter increased by 36.6% to $4.70, compared to $3.44 in the same period last year [2]. Analyst Ratings and Price Targets - Truist raised its price target for Tenet Healthcare to $270 from $240 on February 17, maintaining a Buy rating [1]. - Wells Fargo increased its price target to $265 from $229 on February 16, while keeping an Overweight rating, citing strong capital return potential and alignment with market narratives as key drivers [2]. Company Operations - Tenet Healthcare operates in the healthcare services sector, with its business divided into Hospital Operations and Ambulatory Care segments [3].

Core Viewpoint - Tenet Healthcare Corporation (NYSE:THC) is identified as one of the undervalued momentum stocks, experiencing significant stock price appreciation following its Q4 update, with Wells Fargo raising its price target and maintaining an Overweight rating [1][2]. Financial Performance - For Q4, Tenet reported revenue of $5.53 billion, exceeding the consensus estimate of $5.47 billion by 1% [2]. - Adjusted EPS for Q4 grew 37% year-over-year, reaching $4.70, which surpassed the street expectation of $4.05 [2]. - For FY 2026, Tenet guided revenue between $21.5 billion and $22.3 billion, with adjusted EBITDA projected between $4.485 billion and $4.785 billion [2]. - EPS for FY 2026 is expected to range from $16.19 to $18.47, again above the consensus midpoint of $16.46 [2]. Market Reaction - Following the Q4 results announcement on February 11, the stock rallied 17%, indicating strong investor interest [1]. - Several analysts, including Morgan Stanley, RBC Capital, and KeyBanc, raised their price targets for Tenet, reflecting positive market sentiment [3]. - The stock has shown strong performance with a 57% return in 2025 and an additional 16% increase in 2026, trading close to its 52-week high of $235.8 as of February 20 [3].

Hospital Operations - As of December 31, 2025, the Hospital Operations segment included 50 acute care and specialty hospitals, 132 outpatient facilities, and revenue cycle management services through Conifer Health Solutions[11]. - At December 31, 2025, the total number of licensed beds across all hospitals was 12,494[17]. - Approximately 74% of outpatient centers were located in Arizona and Texas, which may help expand the managed care payer network[20]. - The company employed nearly 100,000 people, with 75,000 in Hospital Operations and 24,000 in Ambulatory Care, as of December 31, 2025[34]. - Approximately 20% of employees in the Hospital Operations segment are represented by labor unions, primarily in California, Florida, and Michigan, which may impact labor costs[44]. - The company faces a shortage of advanced practice clinicians and critical-care nurses, leading to increased wages and benefits to attract and retain staff[41]. - California's minimum nurse-to-patient staffing ratios impact labor costs and may require limiting admissions, adversely affecting revenues[49]. - The company has made significant investments in education and training for newly licensed medical support personnel to address staffing challenges[43]. Ambulatory Care - The Ambulatory Care segment, operated by USPI, held ownership interests in 533 ambulatory surgery centers and 26 surgical hospitals across 37 states[25]. - The company continues to focus on expanding its Ambulatory Care segment through acquisitions and organic growth in physician relationships[28]. - The company continues to focus on expanding its ambulatory care business to improve accessibility and reduce costs for patients compared to hospital visits[56]. Financial Performance and Challenges - The revenue cycle management solutions provided services to approximately 600 hospitals and clients nationwide, with 44% being Tenet and CommonSpirit Health facilities[24]. - The expansion of Medicaid under the Affordable Care Act has increased patient volumes, but reductions in Medicare and Medicaid reimbursement have affected revenues[63]. - The company anticipates potential decreases in patient volumes and revenues due to rising health insurance premiums and shifts to government program coverage starting in 2026[64]. - The One Big Beautiful Bill Act, effective in 2027, introduces new Medicaid work requirements and stricter eligibility checks, which may impact the company's operations[65]. - The competitive landscape includes challenges from not-for-profit organizations and government agencies that may have financial advantages over the company[51]. - The Congressional Budget Office anticipates that millions could lose health insurance due to the OBBBA by 2034, primarily affecting Medicaid and Affordable Care Act coverage[66]. - States are expected to reevaluate their financial plans for 2026 and beyond due to potential material reductions in Medicaid payments and changes to supplemental payment programs[67]. - The company cannot estimate the OBBBA's impact on future business or financial condition, but anticipates decreased payments from Medicare and Medicaid[68]. - Negative productivity adjustments to annual market basket updates and reductions to Medicare and Medicaid DSH payments are ongoing concerns[69]. - Future healthcare funding policy changes may adversely affect patient volumes, revenue mix, and operating costs, potentially leading to a material adverse effect on the company's financial condition[71]. - The company has faced significant costs related to resolving government investigations and qui tam lawsuits, with uncertain future impacts on financial condition[78]. Compliance and Legal Risks - Compliance with HIPAA and state privacy laws is critical, with potential civil penalties for violations that could affect operations[81]. - The company is subject to antitrust laws, with the FTC focusing on preventing transactions that may reduce local patient service options[86]. - Conifer, the company's revenue cycle management service, is subject to various civil and criminal statutes, with ongoing legal risks related to consumer finance and medical billing[87]. - The company emphasizes the importance of compliance with the Foreign Corrupt Practices Act (FCPA) to avoid significant fines and penalties[92]. - Compliance training is provided annually to all employees, emphasizing adherence to the Code of Conduct and ethical standards[97]. - The company’s ethics and compliance department operates independently, reporting directly to the CEO and the board's quality, compliance, and ethics committee[93]. Insurance and Financial Management - The company maintains captive insurance companies to self-insure for the majority of professional and general liability claims, purchasing third-party insurance for catastrophic claims[99]. - Reserves for incurred but not reported claims are maintained based on modeled estimates of losses and related expenses, including self-insured professional liability retentions[100]. - The company faces increased insurance premiums and reduced coverage due to the rise in the number and severity of natural disasters, impacting future insurance availability and costs[101]. - The average effective interest rates for fixed-rate long-term debt range from 4.4% to 7.2%, with a total fair value of $13.285 billion[419]. - The company has no exposure to off-balance sheet financial transactions or special-purpose entities, mitigating associated risks[419]. Reporting and Transparency - The company files annual, quarterly, and current reports with the SEC, ensuring transparency and compliance with regulatory requirements[102]. - Forward-looking statements indicate potential impacts from economic conditions, regulatory changes, and operational risks, highlighting uncertainties in future performance[104]. - Approximately 27% of the company's licensed hospital beds are in states requiring state approval for healthcare facility changes, which may impact expansion plans[82].

Core Viewpoint - Tenet Healthcare Corporation (NYSE: THC) is experiencing significant stock performance improvements following a strong earnings report, with analysts projecting further growth potential. Group 1: Stock Performance - Tenet Healthcare's stock increased by 11.8%, reaching a high of $216.04 after the earnings report [2][5] - The current trading price of THC is $226.35, reflecting a 17.26% increase or $33.31 [4] - The stock has fluctuated between a low of $186.50 and a high of $229 today, with $229 being the highest price over the past year [4] Group 2: Financial Performance - The company's earnings report revealed an EPS of $4.70 for the quarter, surpassing analysts' consensus estimates of $4.05 by $0.65 [3][5] - Tenet Healthcare achieved a net margin of 6.49% and a return on equity of 25.11% [3] - Revenue increased by 8.9% compared to the same quarter last year, indicating strong financial health [3] Group 3: Analyst Projections - RBC Capital set a new price target of $277 for THC, suggesting a potential 22.38% increase from its current price [1][5]

Core Insights - Tenet Healthcare Corporation (THC) reported fourth-quarter 2025 adjusted earnings per share (EPS) of $4.70, exceeding the Zacks Consensus Estimate by 15.2%, with a year-over-year increase of 36.6% [1] - Net operating revenues rose 8.9% year over year to $5.53 billion, surpassing the consensus mark by 1.4% [1] Financial Performance - Adjusted net income for the quarter was $413 million, a 25.2% increase year over year [3] - Adjusted EBITDA improved 12.9% year over year to $1.18 billion, exceeding the estimate of $1.13 billion, with an adjusted EBITDA margin expanding 70 basis points to 21.4% [3] - Salaries, wages, and benefits costs increased 6.1% year over year to $2.2 billion, while supply costs rose 8.6% and net other operating expenses increased 10.8% [4] Segment Performance - Hospital Operations and Services segment recorded net operating revenues of $4.09 billion, up 7.3% year over year, driven by improved Medicaid supplemental revenues and a favorable payer mix [5] - Adjusted EBITDA for the Hospital segment climbed 16.4% year over year to $603 million, with an adjusted EBITDA margin of 14.7%, improving 110 basis points [6] - Ambulatory Care segment's net operating revenues rose 13.8% year over year to $1.43 billion, supported by facility buyouts and expansion of service lines, with adjusted EBITDA at $580 million, a 9.4% increase [7] Financial Position - As of December 31, 2025, Tenet Healthcare had cash and cash equivalents of $2.88 billion, down from $3.02 billion at the end of 2024, while total assets increased to $29.7 billion from $28.9 billion [8] - Long-term debt amounted to $13.1 billion, slightly up from the previous year, with total shareholders' equity increasing to $4.22 billion from $4.17 billion [9] Cash Flow and Share Repurchase - Tenet generated $3.5 billion of net cash from operations in 2025, a 72.9% year-over-year increase, with free cash flows improving 126.7% to $2.5 billion [11] - The company repurchased $198 million in shares during the fourth quarter and $1.4 billion in 2025, with a remaining share repurchase authorization of approximately $1.49 billion [12] 2026 Outlook - Net operating revenues for 2026 are projected to be between $21.5 billion and $22.3 billion, higher than the $21.3 billion in 2025 [13] - Adjusted EBITDA is expected to range from $4.485 billion to $4.785 billion, with an estimated adjusted EBITDA margin of 20.9-21.5%, indicating a potential decline from 2025 [14] - Free cash flow is anticipated to remain between $2.94 billion and $3.29 billion, with capital expenditures projected at $700-$800 million [15]

Group 1 - The core focus of Crude Value Insights is on cash flow and companies that generate it, highlighting value and growth prospects in the oil and natural gas sector [1] - Subscribers have access to a model account with over 50 stocks, in-depth cash flow analyses of exploration and production (E&P) firms, and live chat discussions about the sector [1] Group 2 - A two-week free trial is available for new subscribers, promoting engagement with the oil and gas investment community [2]